Clinical trial
Phase II Study of Range and Schedule of rPA Doses
NCT00170456 · PharmAthene UK Limited, Industry · Completed
Key facts
| NCT number | NCT00170456 |
|---|---|
| Title | Phase II Study of Range and Schedule of rPA Doses |
| Official title | A Double-Blind, Parallel-Group Study of the Safety, Tolerability and Immunogenicity of a Range of Doses and Dosing Schedules of Recombinant (rPA Based) Anthrax Vaccine in Healthy Subjects |
| Lead sponsor | PharmAthene UK Limited, Industry |
| Collaborators | National Institute of Allergy and Infectious Diseases (NIAID) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prevention of Bacillus Anthracis (Anthrax) Infection |
| Intervention type | Biological |
| Interventions | rPA vaccine containing alhydrogel |
| Enrollment | 415 |
| Start date | Mar 1, 2005 |
| Primary completion | Jan 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | Sep 15, 2005 |
| Last update posted | Sep 15, 2008 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: